Fulton Breakefield Broenniman LLC Has $359,000 Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Fulton Breakefield Broenniman LLC trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 676 shares of the medical research company’s stock after selling 148 shares during the quarter. Fulton Breakefield Broenniman LLC’s holdings in Thermo Fisher Scientific were worth $359,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Raleigh Capital Management Inc. boosted its stake in shares of Thermo Fisher Scientific by 49.1% during the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after acquiring an additional 27 shares during the period. Cedar Mountain Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 107.0% during the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after acquiring an additional 46 shares during the period. Operose Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 250.0% during the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock worth $53,000 after acquiring an additional 75 shares during the period. Financial Connections Group Inc. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $53,000. Finally, Valley National Advisers Inc. boosted its stake in shares of Thermo Fisher Scientific by 40.5% during the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock worth $56,000 after acquiring an additional 32 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Marc N. Casper sold 5,547 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $550.62, for a total value of $3,054,289.14. Following the completion of the transaction, the chief executive officer now directly owns 43,608 shares of the company’s stock, valued at $24,011,436.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,277 shares of company stock valued at $28,513,384. Company insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.3 %

Shares of Thermo Fisher Scientific stock traded up $1.87 on Friday, hitting $573.60. 1,438,184 shares of the company’s stock traded hands, compared to its average volume of 1,317,052. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.39. The company has a market capitalization of $218.95 billion, a price-to-earnings ratio of 36.79, a price-to-earnings-growth ratio of 2.41 and a beta of 0.80. The company has a fifty day moving average of $573.60 and a two-hundred day moving average of $529.90. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The company had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.54 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Wall Street Analyst Weigh In

TMO has been the subject of several recent research reports. HSBC boosted their price target on Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Deutsche Bank Aktiengesellschaft boosted their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Barclays boosted their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research note on Thursday. Finally, Raymond James boosted their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $606.76.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.